These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10916802)

  • 1. [Angiotensin converting enzyme inhibitors in arterial hypertension and cardiac failure. The question of the dose].
    González-Juanatey JR
    Med Clin (Barc); 2000; 114 Suppl 2():24-7. PubMed ID: 10916802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ACE inhibitors--an overview].
    Brüggmann J; Eberhardt C
    Fortschr Med; 1993 Jun; 111(16):283-5. PubMed ID: 8330827
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first?
    Fang JC
    Circulation; 2005 Oct; 112(16):2380-2. PubMed ID: 16230494
    [No Abstract]   [Full Text] [Related]  

  • 5. The rationale and indications for angiotensin receptor blockers in heart failure.
    Bybee KA; Das S; O'Keefe JH
    Heart Fail Clin; 2006 Jan; 2(1):81-8. PubMed ID: 17386879
    [No Abstract]   [Full Text] [Related]  

  • 6. [Beginning therapy of heart failure with beta blockers. Do these patients survive longer?].
    MMW Fortschr Med; 2005 Sep; 147(39):10. PubMed ID: 16245769
    [No Abstract]   [Full Text] [Related]  

  • 7. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk factors of asymptomatic first-dose hypotension with angiotensin-converting enzyme inhibitors in chronic heart failure due to systolic dysfunction.
    Thanikachalam S; Manchanda SC
    Indian Heart J; 2003; 55(2):167-71. PubMed ID: 12921333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure.
    Kazi D; Deswal A
    Cardiol Clin; 2008 Feb; 26(1):1-14, v. PubMed ID: 18312901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Converting enzyme inhibitors and acute renal insufficiency--precautions to be taken].
    Guelpa G; Robert D
    Schweiz Rundsch Med Prax; 1991 Aug; 80(34):856-8. PubMed ID: 1925194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [When must, when should, when can ACE inhibitors be administered in heart failure?].
    Jahrmärker H
    Med Klin (Munich); 1993 Aug; 88(8):496-502. PubMed ID: 8413052
    [No Abstract]   [Full Text] [Related]  

  • 13. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular pharmacology (IX). Angiotensin-converting enzyme inhibitors in hypertension and heart failure].
    de Teresa E; Espinosa JS; Gómez Doblas JJ
    Rev Esp Cardiol; 1995 Feb; 48(2):128-41. PubMed ID: 7886264
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical inquiries. Are there big differences among beta-blockers in treating essential hypertension?
    Sontheimer D; Hitchcock K; Saseen J
    J Fam Pract; 2007 Apr; 56(4):312-4. PubMed ID: 17403332
    [No Abstract]   [Full Text] [Related]  

  • 17. [ACE inhibitor therapy until end of life?].
    Werner N
    Dtsch Med Wochenschr; 2004 Oct; 129(44):2375-6. PubMed ID: 15497110
    [No Abstract]   [Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises.
    Palmer BF
    Nephrol Dial Transplant; 2003 Oct; 18(10):1973-5. PubMed ID: 13679467
    [No Abstract]   [Full Text] [Related]  

  • 19. [Angioneurotic edema caused by angiotensin-converting enzyme inhibitors: incidence, clinical characteristics, mechanisms of action].
    Wernze H
    Z Kardiol; 1988; 77 Suppl 3():61-4. PubMed ID: 2850689
    [No Abstract]   [Full Text] [Related]  

  • 20. Initial therapy of hypertension.
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1140-2. PubMed ID: 15863559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.